Form 4: Teva Director Lichtenstein Reports Share Transactions
Statement of Changes in Beneficial Ownership
Chen Lichtenstein, a Director at Teva Pharmaceutical Industries Ltd., reported transactions involving ordinary shares and restricted share units.
Summary
- Chen Lichtenstein, a Director at Teva Pharmaceutical Industries Ltd., reported a transaction on June 5, 2026.
- The transaction involved the acquisition of 14,492 ordinary shares.
- Following this transaction, 19,296 ordinary shares are beneficially owned.
- Restricted share units granted on June 5, 2025, vested on June 5, 2026, totaling 14,492 units.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine insider transactions and vesting of equity awards without significant positive or negative financial disclosures.
Positives
- Director Chen Lichtenstein acquired 14,492 ordinary shares, indicating potential confidence or compensation.
- Vesting of 14,492 restricted share units on June 5, 2026, suggests achievement of performance or service milestones.
Negatives
- The filing indicates a disposal of 19,296 ordinary shares, though the details of this disposal are not explicitly stated in terms of sale or transfer.
Future Outlook
No specific forward-looking statements or guidance were provided in this Form 4 filing.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and activities of company directors and officers. These transactions can offer insights into management's perception of the company's value.
Stakeholder Impact
- Shareholders: The acquisition of shares by a director may be viewed positively, while the disposal of shares warrants attention to understand the reasons behind it.
- Employees: Vesting of restricted share units can be a positive indicator for employees who receive such awards, reflecting company performance or tenure.
Key Dates
| Date | Description |
|---|---|
| 06/05/2025 | Grant date for restricted share units. |
| 06/05/2026 | Vesting date for restricted share units and transaction date for ordinary shares. |
| 06/08/2026 | Date of signature for the filing. |
Keywords
Teva Pharmaceutical Industries, Form 4, Insider Trading, Share Transaction, Director, Restricted Share Units, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.